GLTO vs. LMNL, RLYB, BLRX, LTRN, ELDN, LPTX, CALC, CELU, RPHM, and THTX
Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Liminal BioSciences (LMNL), Rallybio (RLYB), BioLineRx (BLRX), Lantern Pharma (LTRN), Eledon Pharmaceuticals (ELDN), Leap Therapeutics (LPTX), CalciMedica (CALC), Celularity (CELU), Reneo Pharmaceuticals (RPHM), and Theratechnologies (THTX). These companies are all part of the "pharmaceutical preparations" industry.
Galecto (NASDAQ:GLTO) and Liminal BioSciences (NASDAQ:LMNL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
Galecto has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Liminal BioSciences has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Liminal BioSciences has higher revenue and earnings than Galecto. Galecto is trading at a lower price-to-earnings ratio than Liminal BioSciences, indicating that it is currently the more affordable of the two stocks.
Galecto received 16 more outperform votes than Liminal BioSciences when rated by MarketBeat users. Likewise, 58.82% of users gave Galecto an outperform vote while only 48.28% of users gave Liminal BioSciences an outperform vote.
In the previous week, Galecto had 2 more articles in the media than Liminal BioSciences. MarketBeat recorded 2 mentions for Galecto and 0 mentions for Liminal BioSciences. Galecto's average media sentiment score of 1.43 beat Liminal BioSciences' score of 0.00 indicating that Galecto is being referred to more favorably in the media.
Liminal BioSciences has a net margin of 248.35% compared to Galecto's net margin of 0.00%. Galecto's return on equity of -87.11% beat Liminal BioSciences' return on equity.
Galecto currently has a consensus price target of $5.33, suggesting a potential upside of 777.19%. Given Galecto's higher possible upside, research analysts plainly believe Galecto is more favorable than Liminal BioSciences.
14.2% of Galecto shares are owned by institutional investors. Comparatively, 0.7% of Liminal BioSciences shares are owned by institutional investors. 12.1% of Galecto shares are owned by company insiders. Comparatively, 2.2% of Liminal BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Galecto beats Liminal BioSciences on 10 of the 16 factors compared between the two stocks.
Get Galecto News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
